Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

About 75% of all breast cancers are estrogen receptor (ER)-positive. They generally have a more favorable clinical behavior, prognosis, and pattern of recurrence, and endocrine therapy forms the backbone of treatment. Anti-estrogens (such as tamoxifen and fulvestrant) and aromatase inhibitors (such as anastrozole, letrozole, and exemestane) can effectively control the disease and induce tumor responses in a large proportion of patients. However, the majority of patients progress during endocrine therapy (acquired resistance) and a proportion of patients may fail to respond to initial therapy (de novo resistance). Endocrine resistance is therefore of clinical concern and there is great interest in strategies that delay or circumvent it. A deeper knowledge of the molecular mechanisms that drive endocrine resistance has recently led to development of new strategies that have the promise to effectively overcome it. Many resistance mechanisms have been described, and the crosstalk between ER and growth factor receptor signaling pathways seems to represent one of the most relevant. Compounds that are able to inhibit key elements of these pathways and restore endocrine sensitivity have been studied and more are currently under development. The aim of this review is to summarize the molecular pathophysiology of endocrine resistance in breast cancer and its impact on current clinical management.

Original languageEnglish
Pages (from-to)990-1001
Number of pages12
JournalWorld Journal of Clinical Oncology
Volume5
Issue number5
DOIs
Publication statusPublished - Dec 10 2014

Fingerprint

Breast Neoplasms
exemestane
letrozole
Estrogen Receptors
Aromatase Inhibitors
Growth Factor Receptors
Tamoxifen
Therapeutics
Estrogens
Recurrence
Direction compound
Neoplasms
anastrozole
fulvestrant

Keywords

  • Endocrine resistance
  • Estrogen receptor
  • Everolimus
  • Mammalian target of rapamycin
  • PI3K inhibitors

ASJC Scopus subject areas

  • Oncology

Cite this

@article{fa2e0540ab014895b7880911acbcb2b0,
title = "Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions",
abstract = "About 75{\%} of all breast cancers are estrogen receptor (ER)-positive. They generally have a more favorable clinical behavior, prognosis, and pattern of recurrence, and endocrine therapy forms the backbone of treatment. Anti-estrogens (such as tamoxifen and fulvestrant) and aromatase inhibitors (such as anastrozole, letrozole, and exemestane) can effectively control the disease and induce tumor responses in a large proportion of patients. However, the majority of patients progress during endocrine therapy (acquired resistance) and a proportion of patients may fail to respond to initial therapy (de novo resistance). Endocrine resistance is therefore of clinical concern and there is great interest in strategies that delay or circumvent it. A deeper knowledge of the molecular mechanisms that drive endocrine resistance has recently led to development of new strategies that have the promise to effectively overcome it. Many resistance mechanisms have been described, and the crosstalk between ER and growth factor receptor signaling pathways seems to represent one of the most relevant. Compounds that are able to inhibit key elements of these pathways and restore endocrine sensitivity have been studied and more are currently under development. The aim of this review is to summarize the molecular pathophysiology of endocrine resistance in breast cancer and its impact on current clinical management.",
keywords = "Endocrine resistance, Estrogen receptor, Everolimus, Mammalian target of rapamycin, PI3K inhibitors",
author = "Andrea Milani and Elena Geuna and Gloria Mittica and Giorgio Valabrega",
year = "2014",
month = "12",
day = "10",
doi = "10.5306/wjco.v5.i5.990",
language = "English",
volume = "5",
pages = "990--1001",
journal = "World Journal of Clinical Oncology",
issn = "2218-4333",
publisher = "Baishideng Publishing Group",
number = "5",

}

TY - JOUR

T1 - Overcoming endocrine resistance in metastatic breast cancer

T2 - Current evidence and future directions

AU - Milani, Andrea

AU - Geuna, Elena

AU - Mittica, Gloria

AU - Valabrega, Giorgio

PY - 2014/12/10

Y1 - 2014/12/10

N2 - About 75% of all breast cancers are estrogen receptor (ER)-positive. They generally have a more favorable clinical behavior, prognosis, and pattern of recurrence, and endocrine therapy forms the backbone of treatment. Anti-estrogens (such as tamoxifen and fulvestrant) and aromatase inhibitors (such as anastrozole, letrozole, and exemestane) can effectively control the disease and induce tumor responses in a large proportion of patients. However, the majority of patients progress during endocrine therapy (acquired resistance) and a proportion of patients may fail to respond to initial therapy (de novo resistance). Endocrine resistance is therefore of clinical concern and there is great interest in strategies that delay or circumvent it. A deeper knowledge of the molecular mechanisms that drive endocrine resistance has recently led to development of new strategies that have the promise to effectively overcome it. Many resistance mechanisms have been described, and the crosstalk between ER and growth factor receptor signaling pathways seems to represent one of the most relevant. Compounds that are able to inhibit key elements of these pathways and restore endocrine sensitivity have been studied and more are currently under development. The aim of this review is to summarize the molecular pathophysiology of endocrine resistance in breast cancer and its impact on current clinical management.

AB - About 75% of all breast cancers are estrogen receptor (ER)-positive. They generally have a more favorable clinical behavior, prognosis, and pattern of recurrence, and endocrine therapy forms the backbone of treatment. Anti-estrogens (such as tamoxifen and fulvestrant) and aromatase inhibitors (such as anastrozole, letrozole, and exemestane) can effectively control the disease and induce tumor responses in a large proportion of patients. However, the majority of patients progress during endocrine therapy (acquired resistance) and a proportion of patients may fail to respond to initial therapy (de novo resistance). Endocrine resistance is therefore of clinical concern and there is great interest in strategies that delay or circumvent it. A deeper knowledge of the molecular mechanisms that drive endocrine resistance has recently led to development of new strategies that have the promise to effectively overcome it. Many resistance mechanisms have been described, and the crosstalk between ER and growth factor receptor signaling pathways seems to represent one of the most relevant. Compounds that are able to inhibit key elements of these pathways and restore endocrine sensitivity have been studied and more are currently under development. The aim of this review is to summarize the molecular pathophysiology of endocrine resistance in breast cancer and its impact on current clinical management.

KW - Endocrine resistance

KW - Estrogen receptor

KW - Everolimus

KW - Mammalian target of rapamycin

KW - PI3K inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84938076531&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938076531&partnerID=8YFLogxK

U2 - 10.5306/wjco.v5.i5.990

DO - 10.5306/wjco.v5.i5.990

M3 - Article

AN - SCOPUS:84938076531

VL - 5

SP - 990

EP - 1001

JO - World Journal of Clinical Oncology

JF - World Journal of Clinical Oncology

SN - 2218-4333

IS - 5

ER -